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Introduction
This July, PLoS Computational Biology
invited attendees of ISMB/ECCB 2011
(http://www.iscb.org/ismbeccb2011) to
send us short reports of conference
highlights in the guise of PLoS Conference
Postcards. Philip E. Bourne, Editor-in-
Chief, selected three Postcards, which we
received from Poland, Germany, and the
United States of America. If the reports
below capture your interest, you can find
Postcards from past conferences in our
recent collection: http://collections.plos.
org/ploscompbiol/conferencepostcards.
Alfonso Valencia on
‘‘Challenges for Bioinformatics
in Personalized Cancer
Medicine’’
Reported by Pedro Madrigal,
Institute of Plant Genetics
What proteins can be found in a cell?
How do protein complexes form, and
why? How do gene families evolve, and
what drives both gene duplications and
epigenetic modifications? How is bioinfor-
matics influencing personalized treatments
of cancer cases? These four essential—and
yet unanswered—questions were put for-
ward to the ISMB 2011 audience by
Professor Dr. Alfonso Valencia as the
icebreaking launch pad of his keynote talk
to challenge the community to develop a
concerted effort in the field.
In the past few years, it has become
evident that alternative splicing is one
reason why human genomes can produce
so much complexity with so few genes [1],
with more than 50% of multi-exon human
genes able to produce spliced mRNAs.
One type of alternative splicing is charac-
terized by clusters of internal exons being
spliced in a mutually exclusive manner,
but it constitutes a very rare case. It is
known that most alternative splicing
events produce isoforms very different
than the main one, and ‘‘possibly isoforms
we are not detecting are the ones impor-
tant in oncogenic diseases’’, Valencia
pointed out, while indicating that for the
vast majority of alternative isoforms there
is still little evidence of their role as
functional proteins. It has been suggested
that, as a result of some disease events,
potentially deleterious splice variants more
or less dormant within the gene may be
activated and highly expressed [2]. Valen-
cia and colleagues have detected 204 genes
with alternative splice variants, most of
them subtly different from their constitu-
tive counterparts. More information is
available at the APPRIS web server
(http://appris.bioinfo.cnio.es/), developed
at the Spanish National Cancer Centre
(CNIO).
How do proteins manage to distinguish
the right binders (cognate interaction
partners) from the wrong ones? To address
this second question, Valencia reported a
high-throughput docking experiment,
showing that physical docking can often
identify correct binders by predicting the
interaction partners and the organization
of the interaction surface using the distri-
butions of the docking scores for over 1
billion of complex models generated [3].
Valencia’s team has shown that it is
possible to distinguish the structure of
protein complexes by means of docking
algorithms for 56 known interactors in
their unbound form and a background of
922 non-redundant potential interactors.
The formation of nonspecific ‘‘encounter
complexes’’ helps to differentiate true
binders by retaining many different con-
formations close to the final binding
configuration. To achieve a comprehen-
sive definition of protein function, Valen-
cia showed the crucial role of protein
interactions for the divergence generated
during the evolution of protein families
[4]. It is reflected on certain characteristic
patterns of differentially conserved resi-
dues in protein subfamilies, known as
‘‘specificity determining positions’’.
But, why do cancer cells accumulate
structural variations? Is tumor progression
analogous to species evolution? Is gene
duplication a positively selected process, or
is it an inevitable consequence of the
mechanism of DNA replication? Both
chromatin structure and DNA replication
dynamics play a role in eukaryotic geno-
mic evolution, and replication induces
cellular stress, with exposed single-strand
DNA leading to DNA damage. In the
third part of the talk, Valencia put
together DNA replication dynamics [5,6],
chromatin structure and gene age deter-
mination by phylostratification of evolu-
tionary trees for each human gene [7].
Then we obtained a surprising result: old
genes replicate earlier while newer genes
replicate later in the cell cycle. Genes
replicating later are found to be in
heterochromatin-rich regions, and as a
consequence of this process the specializa-
tion and diversification takes place in cell
development. Valencia thus presented
some beautiful examples of ‘‘how compli-
cated things evolve’’, as expressed by
ISMB blogger Dr. Barbara Bryant (Con-
stellation Pharmaceuticals), with whom I
had the opportunity to discuss afterwards.
It seems to be clear that determining
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identify aberrations or alterations in rep-
licating timing associated with disease [6].
The whole picture shows sort of ‘‘mecha-
nistic process instead of selection driven’’,
stressed Valencia.
Subsequently, the talk went deep into
the title topic, highlighting a recent review
in the field [8]. Valencia outlined the
following challenges in personalized can-
cer medicine: next-generation sequencing
must evolve in technology and software;
consequences of mutations in genes and
proteins need to be unraveled; cancer gene
mapping in functional pathways should
make use of protein networks; and text
and database mining have to be more
effectively applied in drug design and
pharmacogenetics. Today, patients’ ge-
nomes are rarely consulted for diagnoses
and treatment planning. Valencia re-
marked on the unique case of a pancreatic
cancer patient whose tumor DNA was
sequenced [9], and for whom ‘‘treatment
was adjusted directly based on genome
analyses’’. The identification of the PALB2
gene, previously associated with breast
cancer predisposition as the second most
commonly mutated gene for hereditary
pancreatic cancer, allowed a better and
rationally targeted personalized treatment
provided by Manuel Hidalgo (CNIO) and
colleagues [10,11].
Last, but not least, Valencia underlined
the contribution of Spain to the Interna-
tional Cancer Genome Consortium
(ICGC) [12]. As a contributing member,
the CLL Research Consortium will gener-
ate a comprehensive catalog of genetic
alterations in 500 independent tumors of
chronic lymphocytic leukemia (CLL). Re-
sults (from just first four cases) of whole-
genome sequencing of CLL combined with
clinical outcomes have identified clinically
relevant mutations that contribute to the
evolution of the disease [13].
The final take-home message was a call
to stimulate the interchange of methods
(software) and data (validated sets) within
the scientific community, promoting in-
harnessed collaborations across research
groups. As Valencia said, ‘‘there is no gain
by developing these systems in isolation or
implementing only everyone’s own soft-
ware’’.
Did Valencia achieve his purpose of
challenging the audience? According to
Bryant, ‘‘I was definitely interested right
from the start. One of the things I liked
about the talk was that he presented
information I had not known about, and
it really got me thinking’’. If we consider
the high number of questions in the
discussion following the presentation—I
counted nine in 11 minutes—the high
impact it had on the attendees becomes
evident. A good talk has the audience
making guesses and I felt that Dr. Valencia
did that well.
To sum up, recent developments in
molecular biology aided by computing are
paving the way in the era of genomics
medicine, and new opportunities are
emerging to detect genetic events leading
to further progression of cancer. In my
opinion, it will change the assumptions
under which conventional treatments such
as radiotherapy or chemotherapy are
applied today to each patient, where the
precise nature of genetic damage and the
mutations involved are not yet well known.
Thus, facing the up-to-date challenges
expounded by Valencia may be consid-
ered as the next stepping stone to the
utilization of personal genomics in forth-
coming individualized cancer treatments.
Milana Frenkel-Morgenstern on
‘‘Potential Functions of Proteins
Encoded by Chimeric RNAs’’
Reported by Noa Sela, Ludwig
Maximilians University
Many interesting lectures were given at
the ISMB 2011 conference in Vienna. In
my opinion, one of the outstanding
sessions in the conference was the work
dedicated to understanding the mysterious
role and function of proteins encoded by
chimeric transcripts, which was presented
by Milana Frenkel-Morgenstern, a post-
doctorate fellow in the CNIO in Madrid,
Spain. Alternative splicing is thought to
influence more than 70% of human genes
and has a major contribution to both
transcriptomic and protemic diversity. It
has been shown to have a role in several
genetic diseases as well as in cancer
development. Chimeric transcripts may
be generated by trans-splicing of pre-
mRNAs or, alternatively, through gene
fusion following translocations and rear-
rangements. Chimeric transcripts are of
special interest since many of them have
been shown to be associated with cancer.
Nevertheless, very few chimeric tran-
scripts, and especially their associated
protein products, have been characterized.
Their functional importance has remained
mysterious and prompted the questions in
the work presented by Dr. Frenkel-Mor-
genstern. The major aim of her work was
to detect and functionally characterize the
chimeric proteins products associated with
genome-wide detection of chimeras by
computational methods. Dr. Frenkel-Mor-
genstern explained that a significant pro-
portion of the chimera transcripts were
also shown to be present in normal cells;
furthermore, many of the chimeras
showed a tissue-specific expression pat-
tern. Among all species analyzed, a
substantial number of chimeras demon-
strated a tendency for protein domain
preservation, indicating constraints on
protein product functionality of chimeric
proteins. Another indication of function-
ality rises from enrichment of membrane
proteins found within chimeras of humans,
mice, and fruit flies. The most striking and
important result of this research is indi-
cated by the fact the 14% of chimeric
proteins in humans may produce a
dominant negative effect in cells. This
finding indicates the importance of these
transcripts’ regulation in cells, albeit their
potential rare abundance. It may also
account for their association with patho-
genesis and cancer.
By using the above genome-wide detec-
tion of chimeras and their functionality
analysis, many specific events of special
interest could be identified. For example,
the chimera resulting from the fusion of the
transcription repressor (Ctbp1) and tran-
scription factor-3 (TCF3) produces a dom-
inant negative protein that deactivates
transcription. Another example showed
the incorporation of signal peptide and
transmembrane domain resulting from the
fusion of solute carrier family 22 member 6
protein (Slc22a6) and thioredoxin domain-
containing protein 12 (Txndc12).
I think that this talk raised an important
discussion about the consequences of
generation of chimeric proteins in cells.
These chimera are likely to have substan-
tially different functions than the original
native proteins. This work indicates that it
is feasible that these chimeras could have
acquired specific functions and that they
might exert dominant negative effects due
to the absence of certain functional
domains and therefore might compete
with functional wild-type proteins.
Generally, I found that this talk was a
good illustration of how experimental
biology can benefit from computational
approaches. The ISMB conference en-
courages the usage of advanced computa-
tional methods that resolve biological
problems, which I believe was also exem-
plified by this talk. My personal feeling is
that the work presented by Dr. Milana
Frenkel-Morgenstern illustrates how im-
portant and valuable the use of computa-
tional methods is along with high-through-
put screening for the analysis of protein
functionality and characterization, and
how they could contribute new hypotheses
and insights for answering biological
questions.
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Phenotypic Data from
Electronic Patient Records with
Molecular Level Systems
Biology’’
Reported by Simon M. Lin,
Marshfield Clinic
Professor Brunak (Technical University
of Denmark and University of Copenha-
gen) presented the first talk in the
BioLINK special session at ISMB 2011
on how to utilize a systems biology
approach to look at diseases phenotypes.
The BioLINK session was organized by
Christian Blaschke (Bioalma, Spain), Lyn-
ette Hirschman, (MITRE, United States),
Hagit Shatkay (University of Delaware,
United States), and Alfonso Valencia
(Spanish National Cancer Research Cen-
tre, Spain).
With the BioLINK session focusing on
data integration and interoperability
across the computational, biological, and
medical fields, Dr. Søren Brunak reported
new gene–disease associations that have
been discovered by integrating phenotype
data with molecular data. In his talk, Dr.
Brunak demonstrated how his group
utilized electronic health records (EHRs)
of Danish patients to extract patient-level
phenotypic data. Unlike the United States’
recent Medicare and Medicaid incentives,
the Danish government launched their
national strategy for EHRs much earlier,
in the 1990s. Fortunately, there are still a
few health care providers in the US, such
as Marshfield Clinic, that have multiple
decades of clinical data in the form of
EHRs. These EHR datasets across the
continents make it possible for future cross
comparison and validation of the findings
by Dr. Brunak’s group.
A limitation indicated in Dr. Brunak’s
talk is that the connections between the
molecular entities (for example, genes) to
diseases are only at an aggregated level. In
specific, the molecular data were text-
mined from the OMIM database and
other scientific literature. As such, patient-
level variations, which are the crux of
personalized medicine, were lost. As Dr.
Brunak pointed out, molecular measure-
ments from a biobank of patients can
potentially solve this problem. The well-
curated biobank with links to EHRs can
be used to characterize the genotype-
phenotype variation at the patient level.
And several well-established biobanks in
the US, such as BioVU at Vanderbilt
University and the Personalized Medicine
Research Project (PMRP) at Marshfield
Clinic, can offer help.
EHRs remain a rather unexplored, but
potentially rich, data source for most
computational biologists. Dr. Brunak’s
avant-garde work represented the fore-
front of translational bioinformatics, which
is defined as ‘‘the storage, retrieval,
analysis, and dissemination of molecular
and genomic information in a clinical
setting’’. Both the International Society of
Computational Biology (ISCB) and Amer-
ican Medical Informatics Association
(AMIA) are actively promoting transla-
tional bioinformatics.
The disciplines of bioinformatics and
medical informatics are closely related and
they can be synergized to achieve the goal
of personalized medicine (Figure 1). The
attendees, speakers, and graduate training
programs at the ISMB and AMIA annual
meetings overlap at the grassroots level.
From an organizational level, the cross-
fertilization of bioinformatics and medical
informatics has already borne fruit. For
instance, the AMIA Summit on Transla-
tional Bioinformatics in 2009 was co-
sponsored by ISCB. Many members of
the two societies were cross-trained in both
bioinformatics and medical informatics.
Speaking from my own experience, I find
my training in medical informatics gave
me an edge working in bioinformatics,
while the working experience in bioinfor-
matics helped me explore further in
medical informatics.
In summary, the convergence of bioin-
formatics and medical informatics can
open new paths of exploration for person-
alized medicine. Dr. Brunak’s talk was a
good indication that more future joint
activities by both ISBM and AMIA will
benefit both current and future genera-
tions of biomedical informatics profession-
als.
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